| Literature DB >> 34071781 |
Heba Ahmed Ali Abdeen1, David Rodriguez-Sanz2, Mahmoud Ewidea3, Dina Mohamed Ali Al-Hamaky4, Marwa Abd El-Rahman Mohamed5, Ahmed Ebrahim Elerian6.
Abstract
Obese women were more susceptible to myalgia because of their significantly lower vitamin D concentrations; the present study investigated the efficacy of vitamin D in addition to an aerobic interval training in the management of obese women with myalgia. Forty-five obese women with vitamin D deficiency and myalgia (30 to 40 years old) were assigned randomly into three equal groups. Group A received an aerobic interval training with vitamin D supplementation, Group B received vitamin D supplementation only, and Group C received aerobic interval training only; participants in all groups were on calorie deficient diets. The study outcomes were the Visual Analog Scale (VAS) for Pain Evaluation, serum vitamin D level, and Cooper 12-Minute Walk Test for Functional Capacity Evaluation, while the Short-Form Health Survey (SF) was used for assessment of quality of life. We detected a significant improvement in pain intensity level, serum vitamin D level, and quality of life in all groups with significant difference between Group A and groups B and C. We also detected a significant improvement in functional capacity in groups A and C, with no significant change in Group B. Aerobic interval training with vitamin D supplementation was more effective for the management of obese women with perceived myalgia.Entities:
Keywords: aerobic interval training; functional capacity; myalgia; obesity; quality of life; vitamin D
Year: 2021 PMID: 34071781 PMCID: PMC8227578 DOI: 10.3390/nu13061819
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flow chart in accordance with the CONSORT statement.
Basic characteristics of participated patients of groups A, B, and C.
| Variable | Group A | Group B | Group C | |
|---|---|---|---|---|
| Age (Year) | 34.8 ± 2.64 | 35.01 ± 2.39 | 35.4 ± 2.69 | 0.83 |
| BMI (kg/m2) | 34.17 ± 1.51 | 34.41 ± 1.85 | 33.96 ± 1.25 | 0.98 |
p-value: probability value.
Variables comparison within and among groups of the study.
| Variables | Groups (Mean ± SD) | ||||
|---|---|---|---|---|---|
| Group A | Group B | Group C | |||
| VAS | Pre-treatment | 6.1 ± 0.89 | 6.3 ± 0.7 | 6.4 ± 0.8 | 0.68 |
| Post-treatment | 2.75 ± 1.25 | 3.03 ± 1.25 | 4.37 ± 0.85 | 0.001 * | |
| Improvement % | 55.4% | 52.07% | 31.01% | ||
| 0.0001 * | 0.0001 * | 0.0001 * | |||
| VitD | Pre-treatment | 17.10 ± 1.16 | 15.90 ± 1.67 | 16.36 ± 1.71 | 0.119 |
| Post-treatment | 23.91 ± 4.29 | 19.87 ± 1.94 | 17.58 ± 2.29 | 0.0001 * | |
| Mean difference | 6.81 | 3.97 | 1.22 | ||
| Improvement % | 39.82% | 24.97% | 10.75% | ||
| 0.0001 * | 0.0001 * | 0.01 * | |||
| PCS | Pre-treatment | 45.60 ± 4.46 | 43.93 ± 3.59 | 45.93 ± 3.53 | 0.330 |
| Post-treatment | 51.87 ± 4.24 | 45.87 ± 4.73 | 47.53 ± 3.54 | 0.001 * | |
| Mean difference | 6.27 | 1.94 | 1.60 | ||
| Improvement % | 13.75% | 4.42% | 3.48% | ||
| 0.0001 * | 0.218 | 0.232 | |||
| MCS | Pre-treatment | 46.20 ± 3.96 | 44.60 ± 3.86 | 45.60 ± 3.43 | 0.507 |
| Post-treatment | 51.53 ± 2.99 | 46.33 ± 4.57 | 47.87 ± 2.44 | 0.001 * | |
| Mean difference | 5.33 | 1.73 | 2.27 | ||
| Improvement % | 11.54% | 3.88% | 4.98% | ||
| 0.0001 * | 0.272 | 0.047 * | |||
| 12MWT | Pre-treatment | 1627.20 ± 68.05 | 1575.13 ± 72.67 | 1615.00 ± 87.01 | 0.161 |
| Post-treatment | 1758.00 ± 102.05 | 1604.93 ± 87.60 | 1687.93 ± 98.88 | 0.0001 * | |
| Mean difference | 130.8 | 29.8 | 72.93 | ||
| Improvement % | 8.04% | 1.89% | 4.52% | ||
| 0.0001 * | 0.319 | 0.041 * | |||
| BMI (kg/m2) | Pre-treatment | 34.17 ± 1.51 | 34.41 ± 1.85 | 33.96 ± 1.25 | 0.98 |
| Post-treatment | 27.75 ± 1.25 | 29.03 ± 1.25 | 27.91 | 0.001 * | |
| Improvement % | 53.1% | 41.98% | 50.6% | ||
| 0.0001 * | 0.0001 * | 0.0001 * | |||
SD: standard deviation p-value: probability value * Significant (p < 0.05).
Post-hoc test between pairwise of groups A, B, and C.
| Variables | Post-hoc (Bonferroni Test) | |||
|---|---|---|---|---|
| Group A and Group B | Group A and Group C | Group B and Group C | ||
|
| Mean difference | −0.27 | −1.62 | −1.34 |
| 95% CI | −1.31–0.76 | −2.65–−0.58 | −2.38–−0.30 | |
| 1.00 | 0.001 * | 0.007 * | ||
|
| Mean difference | 4.03 | 6.33 | 2.29 |
| 95% CI | 1.27–6.78 | 1.53–7.04 | −2.50–3.00 | |
| 0.002 * | 0.001 * | 0.02 | ||
|
| Mean difference | 6.00 | 4.33 | 1.67 |
| 95% CI | 2.15–9.85 | 0.48–8.18 | −5.52–2.18 | |
| 0.001 * | 0.023 * | 0.860 | ||
|
| Mean difference | 5.20 | 3.67 | 1.53 |
| 95% CI | 2.05–8.35 | 0.52–6.82 | −4.68–1.62 | |
| 0.001 * | 0.018 * | 0.695 | ||
|
| Mean difference | 153.07 | 70.07 | 83.00 |
| 95% CI | 65.30–240.83 | −17.70–157.83 | 4.76–170.76 | |
| 0.0001 * | 0.159 | 0.069 | ||
SD: standard deviation p-value: probability value * Significant (p < 0.05).
The relationship between the groups and the level of adherence.
| Adherence | ||||
|---|---|---|---|---|
| Group of the Study | Adherent | Non-Adherent | Total | |
| Group A | Number of patients | 12 | 3 | 15 |
| Expected Number | 10.33 | 4.67 | 15.0 | |
| % within Group | 80% | 20% | 100% | |
| Group B | Number of patients | 10 | 5 | 15 |
| Expected Number | 10.33 | 4.67 | 15 | |
| % within Group | 66.67% | 33.33% | 100% | |
| Group C | Number of patients | 9 | 6 | 15 |
| Expected Number | 10.33 | 4.67 | 15 | |
| % within Group | 60% | 40% | 100% | |
| Total | Number of patients | 31 | 14 | 45 |
| Expected Number | 31.0 | 14.0 | 45.0 | |
| % within Groups | 68.9% | 31.1% | 100% | |